BioHarvest Completes $1.125M Stage 1 CDMO Saffron Program, Advances to Stage 2
BHST•BioHarvest Sciences completed Stage 1 of its $1.125 million CDMO program with SaffronTech, establishing a stable saffron cell bank containing crocin, picrocrocin and safranal. The achievement advances the project to Stage 2, where BioHarvest will generate biomass for pre-commercial testing and holds 25% ownership plus future manufacturing royalties.
1. Stage 1 Completion
BioHarvest Sciences' CDMO division successfully completed Stage 1 of its development agreement with SaffronTech, valued at $1.125 million, establishing a stable saffron cell bank. The cell bank reproduces key bioactive compounds—crocin, picrocrocin and safranal—for nutraceutical and culinary applications.
2. Stage 2 Advancement
Completion of Stage 1 triggered the transition to Stage 2 under the multi-stage agreement. BioHarvest will now scale biomass production in bioreactors to support pre-commercial testing and product formulation.
3. Ownership and Royalties
Under the agreement, BioHarvest holds a 25% ownership stake in the saffron composition and will earn manufacturing royalties on any future compounds produced through its Botanical Synthesis platform.
4. Market and Sustainability Implications
Saffron commands $3,000–$10,000 per kilogram with an annual global market near $500 million, while associated nutraceutical segments exceed a $100 billion total addressable market. BioHarvest’s technology aims to overcome traditional supply constraints, ensuring consistency, purity and scalability for premium saffron ingredients.
